Trial Profile
Metabotropic Glutamate Receptor-5 (mGlur5) Effects on Reward-Related fMRI-BOLD Activation in FHP and FHN
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Mavoglurant (Primary)
- Indications Alcoholism
- Focus Pharmacodynamics
- 25 Nov 2019 Status changed from not yet recruiting to completed.
- 08 Jan 2018 Planned initiation date changed from 30 Nov 2017 to 17 Jan 2018.
- 17 Nov 2017 New trial record